Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MUC16 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MUC16 mutation	Non Small Cell Lung Cancer	MUC16 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
MUC16 mutation	Melanoma	MUC16 mutation	Melanoma	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
MUC16 mutation	HER2 Positive Breast Cancer	MUC16 mutation	HER2 Positive Breast Cancer	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3
MUC16 mutation	HER2 Positive Breast Cancer	MUC16 mutation	HER2 Positive Breast Cancer	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3
MUC16 mutation	Melanoma	MUC16 mutation	Melanoma	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3